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Bulleted statements 
We developed an original strategy for the NIPD of achondroplasia from maternal blood, 
combining ddPCR with minisequencing. This diagnosis provides a rapid and definitive 
diagnosis for parents that are in a painful context of a sudden discovery of abnormal prenatal-
ultrasound findings in the third trimester of pregnancy, as well as an early diagnosis for 
parents aware of the risk because of familial history, allowing an appropriate clinical 
management of pregnancy. 
  
 Abstract 
Background. Achondroplasia is generally detected by abnormal prenatal ultrasound-findings 
in the third trimester of pregnancy, and then confirmed by molecular genetic testing of fetal 
genomic DNA obtained by aspiration of amniotic fluid. This invasive procedure presents a 
small but significant risk for both the fetus and mother. Therefore, non-invasive procedures 
using cell-free-fetal DNA in maternal plasma have been developed for the detection of the 
fetal achondroplasia mutations. Methods. To determine whether the fetus carries the de novo 
nonsense genetic mutation at nucleotide 1138 in FGFR3 gene involved in >99% of 
achondroplasia cases, we developed two independent methods: digital-droplet PCR combined 
with minisequencing, which are very sensitive methods allowing detection of rare alleles. 
Results. We collected 26 plasmatic samples from women carrying fetus at risk of 
achondroplasia, and diagnosed to date a total of five affected fetuses in maternal blood. The 
sensitivity and specificity of our test are respectively 100% [95% confidence interval, 56.6 to 
100%] and 100% [95% confidence interval, 84.5 to 100%]. Conclusions. This novel, original 
strategy for non-invasive prenatal diagnosis of achondroplasia is suitable for implementation 
in routine clinical testing and allows considering extending the applications of these 
technologies in non-invasive prenatal diagnosis of many other monogenic diseases. 
 
 
  
 Introduction 
Achondroplasia (MIM: 100800) is one of the chondrodysplasia which can be diagnosed 
prenatally. This autosomal dominant genetic disease, also known as chondrodystrophic 
dwarfism
1,2
, is the most common nonlethal form of skeletal dysplasia with an estimated 
incidence rate of one in 20,000 live births.  
Achondroplasia is caused by mutations of the transmembrane receptor fibroblast growth 
factor receptor 3 gene FGFR3 (MIM: 134934), which encodes an important regulator of 
linear bone growth
3
. In normal development FGFR3 has a negative regulatory effect on bone 
growth. In achondroplasia, the mutated form of the receptor is constitutively active and this 
leads to severely shortened bones. Approximately 98% of patients with achondroplasia have 
a de novo nonsense genetic mutation in FGFR3 gene with a guanine to adenine transition at 
nucleotide 1138 resulting in a glycine to arginine substitution at position 380 (c.1138G>A, 
p.Gly380Arg), while around 1% present a guanine to cytosine transversion at the same 
position (c.1138G>C, p.Gly380Arg mutation)
4
.  
Achondroplasia is generally detected either on family history of achondroplasia or during 
routine ultrasound in the third trimester of pregnancy, on the basis of characteristic skeletal 
features such as shortened long bones with bowed femora, macrocephaly, frontal bossing and 
trident hand. Molecular prenatal genetic testing offers an early, rapid and reliable diagnosis, 
through the testing of fetal genomic DNA obtained by amniocentesis. These invasive 
procedures present a small but significant risk for both the fetus and mother. Therefore, non-
invasive procedures using cell-free fetal DNA (cffDNA) in maternal plasma have been 
developed for the detection of the fetal achondroplasia mutation. 
In 1997, inspired by the presence of tumor DNA in the plasma and serum of patients 
suffering from cancer
5
, Lo et al. showed the presence of cell-free fetal DNA in the plasma 
 and serum of pregnant women
6
. Therefore, the discovery of cffDNA has opened the field for 
many applications of non-invasive prenatal diagnosis, the vast majority being developed from 
maternal plasma. The DNA extracted from maternal plasma, also known as cell-free DNA 
(cfDNA) or circulating DNA, is formed by a mixture of cf DNA of maternal origin (~ 90%) 
and cfDNA of fetal origin (~ 10%)
7
. The development in 2011 of a droplet digital PCR 
system (ddPCR) allowed to optimize sensitivity, specificity and accuracy for the detection 
and analysis of nucleic acids of low abundance, such as cfDNA. Its principle is based on the 
partitioning of biological sample in tens of thousands of microdroplets of 1 nanoliter, wherein 
the plasmatic DNA fragments are distributed. When compared with the traditional technique 
of real time quantitative PCR, the partitioning step of ddPCR allows to reduce the effects of 
competition due to the presence in plasma of a large excess of maternal DNA, and thus 
increases the specificity and sensitivity of the detection of cfDNA of fetal origin. 
Combining this new, original approach of ddPCR with minisequencing, we developed a new 
strategy for the non-invasive prenatal diagnosis of achondroplasia. Since 2013, close to 190 
plasmatic samples were collected from women at risk of transmitting monogenic disorders, 
such as Duchenne muscular dystrophy, hemophilia, cystic fibrosis, neurofibromatosis type 1 
or achondroplasia. Among those, 26 samples were collected from women carrying fetus at 
risk of achondroplasia, on the basis of abnormal prenatal ultrasound findings in the third 
trimester of pregnancy. This allowed us to diagnose to date a total of five cases of 
achondroplasia in maternal blood.  
 
  
 Methods 
Participants 
Two achondroplastic patients previously diagnosed with FGFR3 mutations by standard 
methods (sequence of the DNA isolated from peripheral blood leucocytes) with c.1138G>A 
and c.1138G>C mutation respectively, were used to create artificial mixtures of DNA with 
very low concentrations and variable proportions of mutant allele to test sensitivity and 
specificity of our assays. A healthy pregnant woman with 22 weeks of pregnancy of a fetus 
with characteristic skeletal features of achondroplasia and whose husband carried the 
c.1138G>A mutation was studied as a positive control to determine whether studying cfDNA 
could be used for the diagnosis of the fetal c.1138G>A mutation. Additionally, a total of 25 
pregnant women with an echographic suspicion of fetal chondrodysplasia were recruited. 
Two additional healthy subjects, negative for FGFR3 mutation, were used as negative 
controls. Written informed consent was obtained prior to venepuncture and the study was 
ethically approved by the Comité Consultatif sur le Traitement de l’Information en matière de 
Recherche dans le domaine de la Santé (CCTIRS – ref 13.386) and the Comité de Protection 
des Personnes (CPP - ref 2014-janvier-13465). In all cases, confirmation of prenatal testing 
result was done by conventional procedures, blindly to the results of non-invasive testing. 
Sample collection 
For each pregnant patient, two tubes of blood were collected by venipuncture in BCT Cell-
Free DNA™ Blood Collection Tube (Streck, Omaha, NE). Plasma samples were separated 
after double centrifugation within 4 days of collection, one at 1600g for 10 minutes and the 
second at 16000g for 10 minutes. The buffy coats were retained. The whole was frozen at -80 
° C in a sterile tube. In all cases, a tissue of fetal origin was taken invasively by puncture of 
 the amniotic fluid (n = 26 samples). For these cases, the blood collection was performed 
before invasive sampling. 
DNA extraction 
cfDNA was extracted from three mL of plasma using the QIAamp Circulating Nucleic Acid 
(Qiagen, Valencia, CA) according to the protocol recommended by the manufacturer in a 
laboratory dedicated exclusively for this purpose. The extracted cfDNA was eluted in 100 µL 
of elution buffer, and stored at -20° C until use. The maternal nuclear DNA and the fetal 
nuclear DNA were extracted respectively from buffy coats or amniotic fluid by the automatic 
extractor Maxwell (Promega, Madison, USA), according to the recommendations provided 
by the manufacturer. 
Sanger sequencing 
For the conventional prenatal diagnosis of achondroplasia from fetal nuclear DNA extracted 
from amniotic fluid, a PCR is performed on thermal cycler Applied Biosystem 9700, 
generating a product of 559 bp, containing the 1138 position of the FGFR3 gene exon 9. 
Primer sequences and cycling conditions are described in Table 1. PCR reactions were 
performed in a total volume of 50 µL with a reaction mixture containing 1 µL of eluted DNA, 
1 µL each primer (10 µM), 3 µL MgCl2 (25 mM) and 5 µL 10X buffer. After a purification 
step, sequencing reactions were performed in a total volume of 20 µL with a reaction mixture 
containing 3 µL of purified PCR product, 1 µL of either forward or reverse primer (10 µM), 2 
µL of 5X BigDye buffer (applied Biosystems) and 4 µL of enzyme Big Dye V1.1. The same 
primers were used for sequencing and cycling conditions are described in Table 1. 
  
 Digital Droplet PCR 
To determine whether the fetus carries a de novo nonsense genetic mutation at nucleotide 
1138 in FGFR3 gene, ddPCR method based on the amplification of the two possible mutant 
alleles –A-allele or C-allele – and the wild-type G-allele was developed. Primer sequences 
are described in Table 1. The presence or absence of amplification for the mutant allele signs 
therefore the presence or absence of mutant FGFR3 sequences of fetal origin in the maternal 
plasma, which indicates a genotype of the fetus FGFR3 mutant or wild-type (WT) 
respectively. Moreover, the amplification of the promoter region of RASSF1A gene 
differentially methylated between the mother and her fetus also ensures the presence of DNA 
of fetal origin
8
 (  (Table 1). 
Droplet digital PCR was performed using the QX100™ Droplet Digital™ PCR System from 
BioRad (Hercules, CA) according to the manufacturer’s instructions. Briefly, three duplex 
PCR are carried out in two replicates: mutant FGFR3 A-allele and WT FGFR3 G-allele are 
amplified together as well as mutant FGFR3 C-allele / WT FGFR3 G-allele and RASSF1A / 
ACTIN B. In each well, 9 µL of the eluted cfDNA solution were mixed with 10 µL of ddPCR 
master mix (BioRad), and 1 µL of each duplex PCR primers/probes. Droplets were generated 
using the Droplet Generator (DG) with 70 µL DG Oil per well with a DG8 cartridge and 
cartridge holder, 21 µL PCR reaction mix, and DG8 gasket. Droplets were dispensed into the 
96-well PCR plate by aspirating 40 µL from the DG8 cartridge into each well. The PCR plate 
was then heat-sealed with a foil seal and the sealed plate was placed in the PCR thermocycler 
(thermal conditions in table 1). After the reaction, the droplets were read using the Droplet 
Reader, and QuantaSoft software converted the data into concentrations using Poisson 
distribution statistical analysis. Detecting a fluorescence indicates that specific amplification 
has occurred, and thus that the genomic target was initially present in the biological sample.  
 The decision algorithm is presented in Figure 1. Briefly, a concomitant amplification of either 
FGFR3 mutant A-allele or mutant C-allele with the FGFR3 WT G-allele indicates an 
achondroplastic fetus. After PCR amplification of cfDNA from healthy pregnant women, 
result was considered positive when >10,000 droplets were generated in each well, and when 
2 replicates showed more than 5 positive droplets for the mutant allele each. The absence of 
amplification of FGFR3 mutant A-allele and mutant C-allele, together with the positive 
amplification of the FGFR3 WT G-allele and the demonstration of the presence of cffDNA 
(through RASSF1A assay) indicated a fetus free of the hotspot mutation of nucleotide 1138 of 
FGFR3 gene. The fetal fraction was estimated through RASSF1A/ B-ACTIN assay as 
previously described
8
. Briefly, co-amplification of RASSF1A and B-ACTIN was performed, 
before and after BstUI digestion (New England Biolabs, Beverly, MA, USA). In absence of 
droplets positive for B-ACTIN after digestion, fetal fraction was calculated as follow: 
[(RASSF1A)post-digestion/(RASSF1A)pre-digestion]%. In order to prevent false negative results due 
to low fetal fraction, in case of fetal fraction <4%, a new analysis is recommended on a 
second sample two weeks later. 
Minisequencing 
PCR amplification and minisequencing reaction primers were designed using the Primer3 
software (http://frodo.wi.mit.edu/primer3/). PCR amplification was performed using the 
LightCycler 480 HRM Master (Roche Diagnostics, Penzberg, Germany). Minisequencing 
was performed using the SNaPshot™ kit (Applied Biosystems, Foster City, CA). All 
reactions were performed according to manufacturer’s protocols. PCR reactions were 
performed in a total volume of 20 µL with a reaction mixture containing 5 µL of eluted DNA 
at a concentration of 2ng/µL, 1 µL each primer (5 µM), 2.4 µL MgCl2 (25 mM) and 10 µL 
2X Master Mix. Primers and cycling conditions for FGFR3 amplification and minisequencing 
assay are described in table 1. After the Exo/sap enzymatic purification step, sequencing 
 reactions were performed in a total volume of 10 µL with a reaction mixture containing 3 µL 
of purified PCR product, 1 µL each primer (2 µM) and 5 µL of SnapShot Multiplex Ready 
Reaction Mix. PCR products were sequenced on 3130xl genetic analyzer (Applied 
Biosystems), analyzed with GeneMapper software (Applied Biosystems) and compared to 
minisequencing results in two achondroplastic subjects with FGFR3 c.1138G>A and 
c.1138G>C mutation respectively and in two healthy controls. 
 
Results 
Genotyping the FGFR3 c.1138G>A and c.1138G>C mutations by ddPCR and 
minisequencing in DNA isolated from peripheral blood leucocytes 
To test the ability of our ddPCR and minisequencing methods to detect of the FGFR3 
mutations in a small quantity of FGFR3 mutant DNA, we used samples mimicking cfDNA 
from pregnant women. Peripheral bloods were obtained from a non-pregnant female carrier 
of the mutant A-allele, a non-pregnant female carrier of the mutant C-allele and two non-
pregnant females blood donor without FGFR3 mutation. Given that cfDNA is characterized 
by a low concentration of fetal DNA and a mix of maternal and fetal DNA, we created 
artificial mixtures of DNA from FGFR3 WT lymphocytes with DNA from FGFR3 mutant 
lymphocytes at very low concentrations and variable proportions of mutation. We tested our 
ddPCR multiplex assays with artificial mixtures of 0.5 ng/µL DNA (containing 50%, 25%, 
12%, 6%, 3%, 1.5%, 0.8%, 0.4% or 0% of mutant allele). As shown in Figure 2, both ddPCR 
FGFR3 mutant A and mutant C allele specific assays are able to discriminate as low as 0.8% 
and 0.4% of mutant DNA, respectively. Similarly, we tested our minisequencing assays with 
artificial mixtures of 0.5 ng/µL DNA (containing 50%, 25%, 12%, 6%, 3%, 1.5%, 0.8% or 
0% of mutant allele). As shown in Figure 3, both minisequencing FGFR3 mutant A and 
 mutant C allele specific assays are able to discriminate down to 1.5 and 3% of mutant DNA, 
respectively. Altogether, these results show that these methods are sensitive and specific 
enough to detect small amounts of FGFR3 mutation in a background of WT DNA in large 
excess. 
Genotyping the FGFR3 c.1138G>A mutation by ddPCR and minisequencing in cfDNA 
from maternal blood 
We also studied a healthy pregnant woman with 22 weeks of pregnancy of a fetus with 
characteristic skeletal features of achondroplasia and whose husband carried the c.1138G>A 
mutation to determine whether ddPCR and minisequencing assays were able to discriminate 
the fetal FGFR3 c.1138G>A mutation from maternal plasma. As shown in figure 4, both 
assays are able to detect the FGFR3 mutant A allele in cfDNA from maternal blood, thus 
confirming the affected status of the fetus (Figure 4). This case is considered as our positive 
control (Table 2, case 22). 
Non-invasive prenatal diagnosis of achondroplasia by ddPCR and minisequencing in 
cfDNA from maternal blood 
We collected 25 additional plasmas from women carrying fetus at risk of achondroplasia, on 
the basis of abnormal prenatal ultrasound findings in the third trimester of pregnancy. All 
samples were tested with both ddPCR and minisequencing assays. As shown in table 2, 
ddPCR and minisequencing analysis classified correctly the healthy and the affected fetuses, 
as compared to the results of Sanger sequencing from fetal DNA obtained through 
conventional prenatal screening. In addition to the case based on family history, which is 
considered as our positive control, four other pregnant women carrying FGFR3 fetuses were 
classified as mutant, being clearly differentiated from negative controls. Altogether, the 
 sensitivity and specificity of our test are 100% respectively [95% confidence interval, 56.6 to 
100%] and 100% [95% confidence interval, 84.5 to 100%]. 
Discussion 
The study of cfDNA is becoming a crucial tool for diagnosis and management in various 
clinical disorders. Indeed, increased levels of cfDNA have been reported in a number of 
clinicopathological conditions such as cancer, stroke, trauma, myocardial infarction, 
autoimmune disorders and pre-eclampsia
8-15
. Additionally, cfDNA from fetal origin can also 
be detected in the plasma of the mother as early as from the 5th week of gestation
16
 opening 
the field for many applications of non-invasive prenatal testing (NIPT) such as fetal gender 
determination
16,17
 or RHD genotyping
18
, chromosomal aneuploidies
19-23
, and an increasing 
number of single gene disorders
24-30
.  
In this work, we developed a novel and original strategy based on droplet digital PCR 
combined with minisequencing, allowing the non-invasive prenatal diagnosis of 
achondroplasia. 26 samples were collected from women carrying fetus at risk of 
achondroplasia, on the basis of family history or abnormal prenatal ultrasound findings in the 
third trimester of pregnancy, such as rhizomelic shortening of the long bones below the first 
percentile associated with macrocephaly. This allowed us to diagnose to date a total of five 
cases of achondroplasia in maternal blood. Four of these were detected by abnormal prenatal 
ultrasound findings in the third trimester of pregnancy and were done in parallel to 
conventional prenatal diagnosis, offering a rapid and definitive diagnosis. The fifth was 
performed at the beginning of the second trimester of pregnancy because of familial history, 
the father being achondroplastic. This diagnosis did not change the management of 
pregnancy; however, it allowed an early diagnosis and an appropriate clinical management of 
 the newborn. This diagnosis has an important psychological impact since parents can then 
prepare themselves before the baby is born. 
Digital PCR has already been proposed as an alternative technique to other quantitative 
techniques for NIPT of aneuploidies
31-33
 as well as monogenic disorders
26-29
. Several groups 
have reported on the diagnosis of achondroplastic fetuses using different analytical 
techniques such as MALDI-TOF, restriction analysis, QF-PCR, quantitative real time PCR 
and more recently NGS
30,34-39
. The early PCR-based methods appear to be suitable in diseases 
for which there is a single hotspot mutation. But because of the inherent properties of 
cffDNA which is characterized by very low absolute and relative concentrations, such 
methods may not be sufficiently sensitive for the delivery of accurate results in all cases. 
Droplet digital PCR, which is based on the partitioning of biological samples, allows to 
optimize the sensitivity, specificity and accuracy for the detection and analysis of nucleic 
acids of low abundance, such as cffDNA. When compared with the traditional technique of 
real time quantitative PCR, the partitioning step of ddPCR reduces the effects of competition 
due to the presence in plasma of a large excess of maternal DNA, and thus increases the 
specificity and sensitivity of the detection of cfDNA of fetal origin. Likewise, 
minisequencing assays have demonstrated a poorer sensitivity as compared to digital PCR, 
probably because of the effects of competition above mentioned. In order to avoid false 
negative results with samples containing a low cfDNA fraction, a second sample will be 
requested two weeks later in case of discordant results between ddPCR and minisequencing 
assays. Because of the low prevalence of this disorder and the subsequent rare recruitment of 
patients at our national level, and given that a single nucleotide accounts for approximately 
99% of cases, the implementation of achondroplasia diagnosis in our routine clinical testing 
by NGS approach appears to be costly and time-consuming.Our combined approach by 
ddPCR and minisequencing is found to be cost-effective and judicious. 
 One limit to the digital PCR approach is that a cfDNA molecule can be counted only if it 
contains the binding sites for both of the digital PCR primers. Owing to the random 
fragmentation of cfDNA, only very short cfDNA molecules, are analyzed by a given digital 
PCR assay. Because of this constraint, the choice of primers and probes is crucial: these must 
target small sequences. Hence, the amplicons used in the present study did not exceed 90 bp 
in length. Furthermore, a non-negligible risk of false-negative sample could be a fetal fraction 
being too low to be detected, even by ddPCR and minisequencing assays. In order to prevent 
this, we used the amplification of a differentially methylated sequence within the RASSF1A 
gene's promoter, a universal marker useful for the detection of false-negative results caused 
by low fetal DNA concentrations in maternal plasma
8
. In order to prevent false negative 
results due to low fetal fraction, a second sample 2 weeks later is recommended in case of 
fetal fraction <4%. Finally, as national French guidelines promote the use of two independent 
techniques in the context of prenatal diagnosis (www.anpgm.fr), we chose to develop 
minisequencing assays specific for the target mutations, and these assays appeared to be as 
effective as ddPCR. 
In conclusion, in this work we have developed a novel, original and cost-effective strategy 
based on droplet digital PCR combined with minisequencing, allowing the non-invasive 
prenatal diagnosis of achondroplasia from pregnant woman plasma. Although this cohort is 
of moderate size, it is important to note that no false positive or false negative were observed 
(sensitivity 100% [95% confidence interval, 56.6 to 100%] and specificity 100% [95% 
confidence interval, 84.5 to 100%]). Promising properties of ddPCR and minisequencing, in 
terms of accuracy, sensitivity and specificity observed for achondroplasia detection allow us 
to consider extending the applications of these technologies in non-invasive prenatal 
diagnosis of many other monogenic diseases. 
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Table 1. Oligonucleotidic sequences of primers and probes, and cycling conditions used in 
the different assays. 
*
 described by Chan et al, 2006 
  
Cycling Conditions
Forward Primer 5' GCG TGC TGA GGT TCT GAG 3'
Reverse Primer 5' GAA TGT TTC GTG CCC CAA AG 3'
Forward Primer 5' GCG TGC TGA GGT TCT GAG 3'
Reverse Primer 5' GAA TGT TTC GTG CCC CAA AG 3'
Forward Primer 5' CAG TGT GTA TGC AGG C 3'
Reverse Primer 5' ACC ACC AGG ATG AAC AG 3'
Mutant A Probe 5' AGC TAC aGG GTG GGC (Fam) (IowaBlack) 3'
Wild-type G Probe 5' AGC TAC GGG GTG GGC (Hex) (IowaBlack) 3'
Forward Primer 5' CAG TGT GTA TGC AGG C 3'
Reverse Primer 5' ACC ACC AGG ATG AAC AG 3'
Mutant C Probe 5' CTA CcG GGT GGG CTT (Fam) (IowaBlack) 3'
Wild-type G Probe 5' CTA CGG GGT GGG CTT (Hex) (IowaBlack) 3'
Forward Primer 5' AGC CTG AGC TCA TTG AGC TG 3'
Reverse Primer 5' ACC AGC TGC CGT GTG G 3'
Probe 5' (Fam) CCA ACG CGC TGC GCA T (MGB) 3'
Forward Primer 5' GCG CCG TTC CGA AAG TT 3'
Reverse Primer 5' CGG CGG ATC GGC AAA 3'
Probe 5' (Vic) ACC GCC GAG ACC GCG TC (MGB) 3'
Forward Primer 5' CAG GCC TCA ACG CCC ATG TC 3'
Reverse Primer 5' GGG GAG CCC AGG CCT TTC TT 3'
Forward Primer
5' aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa ATG CAG GCA 
TCC TCA GCT AC 3'
Reverse Primer
5' tttttttttttttttttttttttttttttt GAA CAG GAA GAA GCC CAC 
CC 3'
1 cycle of 95°C for 7 min/ 40 cycles of 95°C for 30 sec, 58°C for 30 
sec, and 72°C for 30 sec/ 1 cycle of 72°C for 7 min
1 cycle of 96°C for 30 sec/ 30 cycles of 96°C for 20 sec, 50°C for 5 
sec, and 60°C for 4 min
Oligonucleotidic Sequences of Primers and Probes
FGFR3  amplification before Sanger 
Sequencing
Sanger Sequencing Assay
FGFR3
Minisequencing Assay
FGFR3
FGFR3  amplification before 
Minisequencing Assay
1 cycle of 95°C for 10 min/ 55 cycles of 95°C for 10 sec, 68°C for 10 
sec and 72°C for 15 sec/ 1 cycle of 72°C for 7 min
1 cycle of 96°C for 10 sec/ 25 cycles of 96°C for 10 sec, 50°C for 5 sec 
and 60°C  for 30 sec
1 cycle of 95°C for 10 min/ 40 cycles of 94°C for 30 sec and 57°C  for 1 
min/ 1 cycle of 98°C for 10 min
1 cycle of 95°C for 10 min/ 40 cycles of 94°C for 30 sec and 57°C  for 1 
min/ 1 cycle of 98°C for 10 min
1 cycle of 95°C for 10 min/ 40 cycles of 94°C for 30 sec and 57°C  for 1 
min/ 1 cycle of 98°C for 10 min
1 cycle of 95°C for 10 min/ 40 cycles of 94°C for 30 sec and 57°C  for 1 
min/ 1 cycle of 98°C for 10 min
ddPCR Assay
FGFR3_mutant A allele
ddPCR Assay
RASSF1A *
ddPCR Assay
ACTIN B *
ddPCR Assay
FGFR3_mutant C allele
  
Table 2.  FGFR3 fetal genotype classification. Indication for prenatal screening, pregnancy 
term, results of noninvasive testing from plasmatic samples, ddPCR and minisequencing 
assays, and results testing from invasive sample are presented. WT = Wild-type. 
  
FGFR3 
Mutant A allele
(droplets Fam+)
FGFR3 
WT G allele
(droplets Hex+)
Total droplets
Observed % 
Mutant A 
allele
RASSF1A  / B-ACTIN 
FGFR3 
mutant A allele
FGFR3 
WT G allele
1 Abnormal ultrasound findings 24+3 0 603 25396 0% 9% - + Not affected Not affected
2 Abnormal ultrasound findings 33+6 102 1049 24024 9% 8% + + Affected Affected
3 Abnormal ultrasound findings 33 0 1412 24072 0% 11% - + Not affected Not affected
4 Abnormal ultrasound findings 34 41 1144 26696 3% 4% + + Affected Affected
5 Abnormal ultrasound findings 30 0 983 26227 0% 10% - + Not affected Not affected
6 Abnormal ultrasound findings 18 1 1006 26037 0% 8% - + Not affected Not affected
7 Abnormal ultrasound findings 23 0 763 29374 0% 9% - + Not affected Not affected
8 Abnormal ultrasound findings 29 0 1090 29816 0% 12% - + Not affected Not affected
9 Abnormal ultrasound findings 30 78 1034 26201 7% 7% + + Affected Affected
10 Abnormal ultrasound findings 30 0 659 24762 0% 11% - + Not affected Not affected
11 Abnormal ultrasound findings 33 0 1038 25599 0% 11% - + Not affected Not affected
12 Abnormal ultrasound findings 26 0 557 25088 0% 6% - + Not affected Not affected
13 Abnormal ultrasound findings 34+3 0 1320 25808 0% 12% - + Not affected Not affected
14 Abnormal ultrasound findings 34+2 2 1644 25872 0% 11% - + Not affected Not affected
15 Abnormal ultrasound findings 32+4 0 1024 26193 0% 9% - + Not affected Not affected
16 Abnormal ultrasound findings 33+5 0 1437 25180 0% 15% - + Not affected Not affected
17 Abnormal ultrasound findings 32 0 902 26754 0% 10% - + Not affected Not affected
18 Abnormal ultrasound findings 32+6 0 694 28354 0% 8% - + Not affected Not affected
19 Abnormal ultrasound findings 30 0 533 22842 0% 8% - + Not affected Not affected
20 Abnormal ultrasound findings 27 0 518 28889 0% 10% - + Not affected Not affected
21 Abnormal ultrasound findings 32+3 0 1069 28748 0% 8% - + Not affected Not affected
22 Family history (Positive Control) 22 366 5107 27598 7% 6% + + Affected Affected
23 Abnormal ultrasound findings 34+4 65 737 28325 8% 6% + + Affected Affected
24 Abnormal ultrasound findings 12+4 0 839 24872 0% 6% - + Not affected Not affected
25 Abnormal ultrasound findings 32 0 1018 26708 0% 12% - + Not affected Not affected
26 Abnormal ultrasound findings 30+2 0 2002 25862 0% 9% - + Not affected Not affected
Fetal FGFR3  Status 
from invasive sample
Case
Fetal DNA %
Fetal FGFR3  Status 
from non invasive 
plasmatic sample
Pregnancy Term
(weeks of gestation)
Indication of FGFR3  prenatal 
screening
Fetal FGFR3 Genotyping by ddPCR
Fetal FGFR3 Genotyping by 
Minisequencing
  
 
Figure 1. Decision algorithm for ddPCR assay. 
 
  
Figure 2. Validation of the ddPCR assays – serial dilutions for each set of probes with 
artificial mixtures of 0.5 ng/µL DNA from peripheral blood leucocytes with a mutant content 
of 50%, 25%, 12%, 6%, 3%, 1.5%, 0.8%, 0.4% or 0%. A and D. Two-dimensional 
representation of the fluorescence intensity obtained by ddPCR using FGFR3 mutant A (A) 
and FGFR3 mutant C (D) ddPCR assays, respectively. The y and x axes correspond to the 
FAM and HEX intensities, for mutant and WT alleles respectively. Negative droplets (grey 
dots) and positive ones (blue dots for FAM+ only, green dots for HEX+ only and brown for 
FAM+ and HEX+) are assigned as a function of the FAM and HEX florescence amplitudes. 
B and E. One dimensional representation of the fluorescence intensity obtained by ddPCR 
using FGFR3 mutant A (B) and FGFR3 mutant C (E) ddPCR assays, respectively. Each 
column corresponds to one point of the serial dilution mixture of 0.5 ng/µL DNA with a 
mutant content of 50%, 25%, 12%, 6%, 3%, 1.5%, 0.8%, 0.4% or 0%. C and F. Correlation 
between observed vs. theoretical ratios using FGFR3 mutant A (C) and FGFR3 mutant C (F) 
ddPCR assays, respectively. Each point corresponds to one point of the serial dilution 
mixture of 0.5 ng/µL DNA with a mutant content of 50%, 25%, 12%, 6%, 3%, 1.5%, 0.8%, 
0.4% or 0%.  
  
 
Figure 3. Validation of the minisequencing assays – serial dilutions for each set of probes 
with artificial mixtures of 0.5 ng/µL DNA from peripheral blood leucocytes with mutant-A 
allele (up) or mutant-C allele (down) content of 50%, 25%, 12%, 6%, 3%, 1.5%, 0.8% or 0%.  
  
  
Figure 4. Genotyping the FGFR3 c.1138G>A mutation by ddPCR and minisequencing 
assays in plasmatic DNA from maternal blood at 22 weeks of pregnancy. A and D. Two-
dimensional representation of the fluorescence intensity obtained by ddPCR using FGFR3 
mutant A-allele ddPCR assay (A) and RASSF1A/ B-ACTIN assay (D), respectively. B and 
E. One dimensional representation of the fluorescence intensity obtained by ddPCR using 
FGFR3 mutant A-allele ddPCR assay (B) and RASSF1A/ B-ACTIN assay before and after 
BstUI digestion (E), respectively. C. Minisequencing electrophoregram. The brown pic 
corresponds to the size marker, the black pic corresponds to the WT G-allele, and the red pic 
corresponds to the mutant A-allele. 
